


29.

A compound of formula I:



wherein R¹ and R² independently represent

(i) -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl or -C₁₋₃ alkylC₃₋₈ cycloalkyl,

or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or -OC₁₋₆alkyl groups;

(ii) -(CH₂)_eAr¹ or -(CH₂)_eOAr¹;

or NR¹R² together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more -(CO)_n(CH₂)_iAr¹, -(CO)_nC₁₋₆ alkylAr¹Ar², -(CO)_nC₁₋₆alkyl, -(CH₂)_rOH, -(CH₂)_rO(CH₂)_pOH, -(CH₂)_rOC₁₋₆ alkyl, -O(CH₂)_rAr¹, -(CH₂)_rSO₂Ar¹, piperidin-1-yl, -(CH₂)_iCONR⁸R⁹, -NR¹⁰(CO)_n(CH₂)_iAr¹, -NR¹⁰(CO)_nC₁₋₆ alkylC₃₋₆ cycloalkyl, -NR¹⁰(CO)_nC₁₋₆ alkylDiC₃₋₆ cycloalkyl, -CONR¹⁰(CH₂)_iAr¹,

halogen, -NSO₂C₁₋₆alkyl, -SO₂NR¹⁰R¹¹, -SO₂C₁₋₆ alkyl or -SO₂Ar² groups;

R³ represents -C₁₋₆alkylNH₂, -C₂₋₆alkenylNH₂, -C₂₋₆alkynylNH₂, -C₁₋₆alkylINR¹⁴R¹⁸, -(CH₂)_hCONR¹⁴R¹⁸, -(CH₂)_hCOC₁₋₆alkyl, -(CH₂)_dCHNR¹⁸CONR²⁰R²¹, -(CH₂)_mNR¹⁸CONR¹⁴R¹⁸, -(CH₂)_dNR¹⁸Ar³, -(CH₂)_dCONR¹⁸Ar³, -(CH₂)_hCOOR¹⁸, -(CH₂)_cAr³, -O(CH₂)_cAr³, -(CH₂)_dCO(CH₂)_sAr³ or -(CH₂)_dOAr³;

or R³ represents -(CH₂)_c-2,4-imidazolidinedione, -(CH₂)_c(piperidin-4-yl), -

(CH₂)_c(piperidin-3-yl), -(CH₂)_c(piperidin-2-yl), -(CH₂)_c(morpholin-3-yl) or -

(CH₂)_c(morpholin-2-yl) optionally substituted on nitrogen by -(CO)_iC₁₋₆alkyl, -

(CO)_i(CH₂)_cAr² or -C(=NH)NH₂;

or R³ represents -(CH₂)_cdibenzofuran optionally substituted by -C₁₋₆alkyl or halogen;

or R³ represents -(CH₂)_c-thioxanthen-9-one;

R⁴ represents hydrogen, -C₁₋₆ alkyl, -C₁₋₃ alkylC₃₋₆ cycloalkyl, -(CH₂)_qAr², -C₁₋₄alkyl-X-R⁷, -C₁₋₄alkyl SO₂C₁₋₄ alkyl, -C₁₋₆alkylINR¹²R¹³ or -C₁₋₆ alkylINR¹²COC₁₋₆ alkyl;

R⁵ represents hydrogen, or R⁴R⁵ together with the carbon to which they are attached form a C₅₋₇ cycloalkyl ring;

R^6 represents hydrogen or $-C_{1-6}\text{alkyl}$, or R^6 and R^4 together with the N and C atoms to which they are respectively attached form a pyrrolidine ring;

R^7 represents hydrogen, $-(\text{CH}_2)_w\text{NR}^{12}\text{R}^{13}$, $-(\text{CH}_2)_u\text{Ar}^2$ or $-(\text{CH}_2)_w\text{NR}^{12}\text{COC}_{1-6}\text{alkyl}$;

R^8 , R^9 , R^{16} and R^{17} independently represent hydrogen, $-C_{1-6}\text{alkyl}$, $-C_{3-6}\text{cycloalkyl}$, $-C_{1-3}\text{alkylC}_{3-6}\text{cycloalkyl}$, $-C_{2-6}\text{alkenyl}$ or NR^8R^9 or $\text{NR}^{16}\text{R}^{17}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by $-C_{1-6}\text{alkyl}$, $-\text{COphenyl}$ or $-\text{SO}_2\text{methyl}$;

R^{10} , R^{11} , R^{12} , R^{13} , R^{15} , R^{18} , R^{20} and R^{21} independently represent hydrogen or $-C_{1-6}\text{alkyl}$;

R^{14} , R^{19} and R^{22} independently represent hydrogen, $-C_{1-6}\text{alkyl}$, $-C_{3-6}\text{cycloalkyl}$ or $-(\text{CH}_2)_x\text{Ar}^4$ or $\text{NR}^{14}\text{R}^{18}$ or $\text{NR}^{15}\text{R}^{22}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or $N-C_{1-6}\text{alkylpiperazinyl}$;

Ar^1 represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, $-C_{1-6}\text{alkyl}$, hydroxy, $-\text{OC}_{1-6}\text{alkyl}$, CF_3 , nitro, $-\text{Ar}^2$ or $-\text{OAr}^2$ groups;

Ar^2 represents phenyl optionally substituted by one or more halogen, $-C_{1-6}\text{alkyl}$, hydroxy, $-\text{OC}_{1-6}\text{alkyl}$, $-\text{CF}_3$ or nitro groups;

Ar^3 represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more $-\text{CO}(\text{CH}_2)_a\text{Ar}^4$, $-(\text{CH}_2)_y\text{Ar}^4$, $-(\text{CH}_2)_y\text{COAr}^4$, $-(\text{CO})_a\text{C}_{1-6}\text{alkyl}$, $-(\text{CO})_a\text{C}_{2-6}\text{alkenyl}$, $-(\text{CO})_a\text{C}_{2-6}\text{alkynyl}$, $-(\text{CO})_a\text{C}_{3-8}\text{cycloalkyl}$, $-(\text{CO})_a\text{C}_{1-6}\text{haloalkyl}$, halogen, $-\text{COCH}_2\text{CN}$, $-(\text{CH}_2)_b\text{NR}^{16}\text{R}^{17}$, $-(\text{CH}_2)_b\text{NHC}(\text{=NH})\text{NH}_2$, $-\text{CYNR}^{16}(\text{CO})_a\text{R}^{17}$, $-(\text{CH}_2)_b\text{NR}^{15}\text{COR}^{19}$, $-(\text{CH}_2)_b\text{CONR}^{15}\text{R}^{22}$, $-(\text{CH}_2)_b\text{NR}^{15}\text{CONR}^{15}\text{R}^{22}$, $-(\text{CH}_2)_b\text{CONR}^{15}(\text{CH}_2)_j\text{NR}^{15}\text{R}^{22}$, $-(\text{CH}_2)_b\text{SO}_2\text{NR}^{15}\text{R}^{22}$, $-(\text{CH}_2)_b\text{SO}_2\text{NR}^{15}\text{COAr}^2$, $-(\text{CH}_2)_b\text{NR}^{15}\text{SO}_2\text{R}^{19}$, $-\text{SO}_2\text{R}^{19}$, $-\text{SOR}^{19}$, $-(\text{CH}_2)_z\text{OH}$, $-\text{COOR}^{15}$, $-\text{CHO}$, $-\text{OC}_{1-10}\text{alkyl}$, $-\text{O}(\text{CH}_2)_i\text{NR}^{15}\text{R}^{22}$, $-\text{O}(\text{CH}_2)_i\text{NHC}(\text{=NH})\text{NH}_2$, $-\text{O}(\text{CH}_2)_b\text{CONR}^{16}\text{R}^{17}$, $-\text{O}(\text{CH}_2)_k\text{COOR}^{15}$, $-\text{O}(\text{CH}_2)_j\text{OAr}^2$, $-\text{O}(\text{CH}_2)_b\text{Ar}^2$, 3-phenyl-2-pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

Ar^4 represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, $-C_{1-6}\text{alkyl}$, hydroxy, $-\text{OC}_{1-6}\text{alkyl}$, $-\text{CF}_3$, nitro or $-\text{CONH}_2$ groups;

X and Y independently represent O or S;

a, f, k, s and n independently represent 0 or 1;

b, c, r, x, y and z independently represent an integer 0 to 2;

d, g and u independently represent 1 or 2;

e, h, q and w independently represent an integer 1 to 3;

j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4;

t independently represents an integer 0 to 3;

and salts and solvates thereof.

30. A compound according to claim 29 wherein R⁴ represents -C₁₋₆ alkyl, R⁵ represents hydrogen or R⁴R⁵, together with the carbon to which they are attached, forms a cyclohexyl ring, and R⁶ represents hydrogen or methyl.

31. A compound according to claim 30 wherein R⁴ represents -C₁₋₆ alkyl and R⁵ and R⁶ represent hydrogen.

32. A compound according to claim 31 wherein R⁴ represents -CH₂CHMe₂ and R⁵ and R⁶ represent hydrogen.

33. A compound according to claim 29 wherein NR¹R² together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-tetrahydroisoquinoline optionally substituted by a -(CO)_n(CH₂)_tAr¹, -(CO)_nC₁₋₆alkyl, -(CH₂)_tCONR⁸R⁹, -NR¹⁰(CO)_n(CH₂)_tAr¹, -NR¹⁰(CO)_nC₁₋₃ alkylC₃₋₆ cycloalkyl, -NR¹⁰(CO)_nC₁₋₆ alkylidC₃₋₆ cycloalkyl, -(CH₂)_tOC₁₋₆ alkyl, -(CH₂)_tO(CH₂)_pOH, piperidin-1-yl, -(CH₂)_tOH or -CONR¹⁰(CH₂)_tAr¹ group.


34. A compound according to claim 33 wherein NR¹R² together represents morpholinyl or piperazinyl optionally N-substituted by -(CO)_nC₁₋₆ alkyl, piperazinyl N-substituted by -(CO)_n(CH₂)_tAr¹, piperidinyl substituted by -NR¹⁰(CO)_n(CH₂)_tAr¹ or piperidinyl substituted by -(CH₂)_tCONR⁸R⁹.

35. A compound according to claim 29 wherein R³ represents -(CH₂)_c-2,4-imidazolidinedione-3-yl, -(CH₂)_c-thioxanthen-9-one-3-yl, -(CH₂)_cAr³, -O(CH₂)_cAr³, -(CH₂)_dOAr³ or -(CH₂)_ddibenzofuran.

36. A compound according to claim 35 wherein R³ represents -OCH₂Ar³, -CH₂OAr³ or dibenzofuran.

37. A compound according to claim 36 wherein R³ represents -CH₂OAr³.

38. A compound according to claim 29 wherein R⁴ and R⁵ have the stereochemical orientation shown in formula (Ia):



39. A compound of formula (I) which is:

(2S)-2-[((2S)-2-{{2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{{4-[(2-phenylacetyl)amino]-1-piperidinyl]carbonyl} oxy]phenyl}propanoic acid;

(2S)-2-{{(2S)-4-Methyl-2-[(2-{{3-(1-piperidinyl)carbonyl}-2-naphthyl}oxy]acetyl]amino}pentanoyl}amino}-3-{{4-[(2-phenylacetyl)amino]-1-piperidinyl]carbonyl}oxy]phenyl}propanoic acid;

(2S)-3-{{4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl]carbonyl} oxy]phenyl}-2-{{(2S)-4-methyl-2-{{2-[4-(1-piperidinyl)carbonyl]phenoxy}acetyl}amino}pentanoyl}amino}propanoic acid;

(2S)-2-{{(2S)-4-Methyl-2-{{2-[4-(1-piperidinyl)carbonyl]phenoxy}acetyl}amino}pentanoyl}amino}-3-{{4-[(4-morpholinyl)carbonyl]oxy]phenyl} propanoic acid;

(2S)-3-{{4-[(4-(Aminocarbonyl)-1-piperidinyl)carbonyl]oxy}phenyl}-2-{{(2S)-4-methyl-2-{{2-[4-(1-piperidinyl)carbonyl]phenoxy}acetyl}amino}pentanoyl}amino}propanoic acid;

(2S)-3-{{4-[(4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl)carbonyl] oxy]phenyl}-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-3-{{4-[(4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl)carbonyl] oxy]phenyl}-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-2-{{(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino}-3-{{4-[(4-morpholinyl)carbonyl]oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino}-3-{{4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl}oxy] phenyl}propanoic acid;

(2S)-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methyl pentanoyl}amino}-3-{{4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl}oxy] phenyl}propanoic acid;

(2S)-3-{{4-[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl}-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-3-{{4-[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl}-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-3-{{4-[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl}-2-{{(2S)-2-{{2-(2,4-dichlorophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-3-{{4-[(4-(Aminocarbonyl)-1-piperidinyl)carbonyl]oxy}phenyl}-2-{{(2S)-2-{{2-(2-iodophenoxy)acetyl}amino}-4-methylpentanoyl}amino}propanoic acid;

(2S)-2-{{(2S)-2-{{2-[2-(Tert-butyl)phenoxy}acetyl}amino}-4-methyl pentanoyl}amino}-3-{{4-[(4-(1-piperidinyl)carbonyl)-1-piperidinyl]carbonyl}oxy} phenyl}propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-[((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl)amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-[((2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl)amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-[((2S)-2-[(2-[2-(Tert-butyl)phenoxy]acetyl)amino]-4-methyl pentanoyl)amino]-3-[4-({[4-[(4-fluorobenzyl)amino]carbonyl}-1-piperidinyl)carbonyl]oxy)phenyl]propanoic acid;

(2S)-2-[((2S)-2-[(2-(2,4-Dichlorophenoxy)acetyl)amino]-4-methyl pentanoyl)amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[((2S)-2-[(2-(2-Benzoylphenoxy)acetyl)amino]-4-methyl pentanoyl)amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-propylphenoxy)acetyl]amino} pentanoyl)amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[((2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl)amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[((2S)-2-[(Benzyl)carbonyl]amino)-4-methylpentanoyl)amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-3-[4-({[4-(2-Furoyl)-1-piperazinyl]carbonyl}oxy)phenyl]-2-[((2S)-2-[(2-iodophenoxy)acetyl]amino)-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[((2S)-2-[(2-(2-Cyclohexylphenoxy)acetyl)amino]-4-methyl pentanoyl)amino]-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

(2S)-2-[((2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl)amino]-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

(2S)-3-(4-{{[4-(2-(4-Chlorophenyl)acetyl)amino]-1-piperidinyl} carbonyl}oxy)phenyl]-2-[((2S)-2-{{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[((2S)-2-[(2-(2-Benzoylphenoxy)acetyl)amino]-4-methyl pentanoyl)amino]-3-[4-{{[4-(2-(4-chlorophenyl)acetyl)amino]-1-piperidinyl} carbonyl}oxy]phenyl]propanoic acid;

(2S)-3-(4-{{[4-(2-(4-Chlorophenyl)acetyl)amino]-1-piperidinyl} carbonyl}oxy)phenyl]-2-[((2S)-2-{{[2-(2-iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]propanoic acid;

(2S)-2-{{(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino}-3-{4-{{(4-[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl}carbonyl}oxy}phenyl)propanoic acid;

(2S)-3-(4-{{(4-[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl} carbonyl}oxy}phenyl)-2-{{(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino}propanoic acid;

(2S)-3-(4-{{(4-[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl} carbonyl}oxy}phenyl)-2-{{(2S)-4-methyl-2-[(2-[3-(1-piperidinylcarbonyl)-2-naphthyl]oxy)acetyl]amino}pentanoyl}amino}propanoic acid;

(2S)-2-{{(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino}-3-{4-{{(4-[(2-cyclohexylacetyl)amino]-1-piperidinyl}carbonyl} oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino}-3-{4-{{(4-[(2,2-dicyclohexylacetyl)amino]-1-piperidinyl} carbonyl}oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-4-Methyl-2-{{2-(2-methylphenoxy)acetyl}amino} pentanoyl}amino}-3-{{(4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl} oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-2-{{2-(2-Cyclohexylphenoxy)acetyl}amino}-4-methyl pentanoyl}amino}-3-{4-{{(4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl} oxy}phenyl}propanoic acid;

(2S)-3-{{4-{{(4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl} oxy}phenyl}-2-{{(2S)-2-{{2-(2-cyclohexylphenoxy)acetyl}amino}-4-methyl pentanoyl}amino}propanoic acid;

and salts and solvates thereof.

40. A compound of formula (I) which is:

(2S)-2-{{(2S)-2-{{2-(2-Iodophenoxy)acetyl}amino}-4-methyl pentanoyl}amino}-3-{{(4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino}-3-{{(4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;

(2S)-3-{{4-{{(4-Acetyl-1-piperazinyl)carbonyl}oxy}phenyl}-2-{{(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl}amino}propanoic acid};

(2S)-2-{{(2S)-2-{{2-(2-Cyclohexylphenoxy)acetyl}amino}-4-methyl pentanoyl}amino}-3-{{(4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;

(2S)-2-{{(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl}amino}-3-{{(4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl} oxy}phenyl}propanoic acid;

(2S)-3-{{4-{{(4-[(2-Benzoyl-1-piperazinyl)carbonyl}oxy}phenyl)-2-{{(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl}amino}propanoic acid};

(2S)-3-(4-{{(4-Acetyl-1-piperazinyl)carbonyl}oxy}phenyl)-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
(2S)-2-{{(2S)-2-[(2-[2-(Tert-butyl)phenoxy]acetyl)amino]-4-methyl pentanoyl}amino}-3-[4-{{[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy}phenyl] propanoic acid;
(2S)-2-{{(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino}-3-[4-{{[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy}phenyl] propanoic acid;
(2S)-3-(4-{{(4-Benzoyl-1-piperazinyl)carbonyl}oxy}phenyl)-2-[(2S)-4-methyl-2-{{[2-(2-methylphenoxy)acetyl]amino}pentanoyl}amino]propanoic acid;
(2S)-3-(4-{{(4-Benzoyl-1-piperazinyl)carbonyl}oxy}phenyl)-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;
and salts and solvates thereof.

41. A compound of formula (I) which is:

(2S)-3-(4-{{(4-Acetyl-1-piperazinyl)carbonyl}oxy}phenyl)-2-[(2S)-4-methyl-2-{{[2-(2-methylphenoxy)acetyl]amino}pentanoyl}amino]propanoic acid;
(2S)-3-[4-{{[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino) propanoic acid;
(2S)-3-[4-{{[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]-2-{{(2S)-2-[(2-[2-(tert-butyl)phenoxy]acetyl)amino]-4-methylpentanoyl}amino} propanoic acid;
(2S)-2-[(2S)-4-Methyl-2-{{[2-(2-methylphenoxy)acetyl]amino} pentanoyl}amino]-3-[4-{{(4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;
(2S)-3-[4-{{[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]-2-[(2S)-2-{{[2-(2-benzoylphenoxy)acetyl]amino}-4-methylpentanoyl}amino] propanoic acid;
(2S)-2-{{(2S)-2-{{[2-(4-(Aminocarbonyl)phenoxy]acetyl)amino}-4-methylpentanoyl}amino}-3-[4-{{[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]propanoic acid;
and salts and solvates thereof.

42. A compound of formula (I) which is:

(2S)-3-[4-{{[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]-2-[(2S)-4-methyl-2-{{[2-(2-methylphenoxy)acetyl]amino}pentanoyl}amino] propanoic acid or a salt or solvate thereof.

43. A compound of formula (I) according to claim 42 which is:

(2S)-3-[4-{{[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy}phenyl]-2-[(2S)-4-methyl-2-{{[2-(2-methylphenoxy)acetyl]amino}pentanoyl}amino] propanoic acid potassium salt or a solvate thereof.

44. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.


45. A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination together with a long acting β_2 adrenergic receptor agonist.

46. A compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical.

47. A method of treatment or prophylaxis of inflammatory diseaseseg. asthma which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof.

48. A process for preparation of a compound of formula (I) as defined in claim 29 which comprises


(a) hydrolysis of a carboxylic acid ester of formula (II)



wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or


(b) deprotecting a compound of formula (I) which is protected.

49. A compound of formula (II)




wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester.

50. A compound of formula (VI)




wherein P_1 represents Boc, R^4 , R^5 and R^6 are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

51. A compound of formula (VII)




wherein P_1 represents Boc, R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

52. A compound of formula (VIII)



wherein R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, HX is a hydrohalic acid and R represents a group capable of forming a carboxylic acid ester.

53. A compound of formula (XIII)



wherein R^4 , R^5 and R^6 are as defined in claim 29 and R' represents a hydroxy functionalised polystyrene resin.